Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19

NCT04649515 is registered in ClinicalTrials.gov with Tychan Pte Ltd. as lead sponsor.

NCT NCT04649515
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04649515 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 3 Multi-Site, Randomised, Placebo Controlled, Double Blind, Single Dose Study of TY027 for Early Treatment of COVID-19
Lead sponsor
Tychan Pte Ltd.
Phase
Phase 3
Overall status
Terminated
Start date
December 4, 2020
Completion date
March 4, 2022
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease-2019 (covid-19)